Trial Profile
An Exploratory, Observational, Multicentre Study to Investigate the Impact of the Presence of JAK2 (V617F) Mutation on Treatment Response in Patients With Essential Thrombocythaemia Treated With XAGRID (Anagrelide Hydrochloride).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Anagrelide (Primary)
- Indications Embolism and thrombosis; Essential thrombocythaemia
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms EMIX
- Sponsors Shire
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Feb 2013 Planned End Date changed from 1 Jan 2014 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 24 Jan 2013 Planned End Date changed from 1 May 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.